Logo image of APYX

APYX MEDICAL CORP (APYX) Stock Fundamental Analysis

NASDAQ:APYX - Nasdaq - US03837C1062 - Common Stock - Currency: USD

0.8905  -0.02 (-2.1%)

Fundamental Rating

2

Overall APYX gets a fundamental rating of 2 out of 10. We evaluated APYX against 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of APYX have multiple concerns. APYX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

APYX had negative earnings in the past year.
In the past year APYX has reported a negative cash flow from operations.
In the past 5 years APYX always reported negative net income.
In the past 5 years APYX always reported negative operating cash flow.
APYX Yearly Net Income VS EBIT VS OCF VS FCFAPYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

The Return On Assets of APYX (-36.18%) is worse than 60.21% of its industry peers.
Looking at the Return On Equity, with a value of -165.12%, APYX is doing worse than 70.16% of the companies in the same industry.
Industry RankSector Rank
ROA -36.18%
ROE -165.12%
ROIC N/A
ROA(3y)-34.86%
ROA(5y)-28.54%
ROE(3y)-98.96%
ROE(5y)-68.76%
ROIC(3y)N/A
ROIC(5y)N/A
APYX Yearly ROA, ROE, ROICAPYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

APYX has a better Gross Margin (61.04%) than 60.73% of its industry peers.
In the last couple of years the Gross Margin of APYX has declined.
APYX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.12%
GM growth 5Y-2.02%
APYX Yearly Profit, Operating, Gross MarginsAPYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

More info and screens

3

2. Health

2.1 Basic Checks

APYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APYX has more shares outstanding
The number of shares outstanding for APYX has been increased compared to 5 years ago.
Compared to 1 year ago, APYX has a worse debt to assets ratio.
APYX Yearly Shares OutstandingAPYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
APYX Yearly Total Debt VS Total AssetsAPYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -0.65, we must say that APYX is in the distress zone and has some risk of bankruptcy.
APYX's Altman-Z score of -0.65 is in line compared to the rest of the industry. APYX outperforms 41.88% of its industry peers.
APYX has a Debt/Equity ratio of 2.39. This is a high value indicating a heavy dependency on external financing.
APYX has a Debt to Equity ratio of 2.39. This is amonst the worse of the industry: APYX underperforms 83.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.39
Debt/FCF N/A
Altman-Z -0.65
ROIC/WACCN/A
WACC11.99%
APYX Yearly LT Debt VS Equity VS FCFAPYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

APYX has a Current Ratio of 5.26. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.
APYX has a Current ratio of 5.26. This is in the better half of the industry: APYX outperforms 76.96% of its industry peers.
APYX has a Quick Ratio of 4.56. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.56, APYX is in the better half of the industry, outperforming 78.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 4.56
APYX Yearly Current Assets VS Current LiabilitesAPYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

APYX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.06%.
APYX shows a decrease in Revenue. In the last year, the revenue decreased by -8.12%.
Measured over the past years, APYX shows a quite strong growth in Revenue. The Revenue has been growing by 11.24% on average per year.
EPS 1Y (TTM)-8.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)-8.12%
Revenue growth 3Y-0.29%
Revenue growth 5Y11.24%
Sales Q2Q%-3%

3.2 Future

The Earnings Per Share is expected to grow by 18.24% on average over the next years. This is quite good.
APYX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.40% yearly.
EPS Next Y37.08%
EPS Next 2Y17.62%
EPS Next 3Y13.24%
EPS Next 5Y18.24%
Revenue Next Year1.58%
Revenue Next 2Y4.61%
Revenue Next 3Y8.36%
Revenue Next 5Y41.4%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
APYX Yearly Revenue VS EstimatesAPYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
APYX Yearly EPS VS EstimatesAPYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APYX. In the last year negative earnings were reported.
Also next year APYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APYX Price Earnings VS Forward Price EarningsAPYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APYX Per share dataAPYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

APYX's earnings are expected to grow with 13.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.62%
EPS Next 3Y13.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APYX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APYX MEDICAL CORP

NASDAQ:APYX (4/25/2025, 8:00:00 PM)

0.8905

-0.02 (-2.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-13 2025-03-13/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners41.63%
Inst Owner Change-0.63%
Ins Owners13.56%
Ins Owner Change0%
Market Cap33.65M
Analysts77.78
Price Target4.08 (358.17%)
Short Float %0.45%
Short Ratio2.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.26%
Min EPS beat(2)26.05%
Max EPS beat(2)26.47%
EPS beat(4)3
Avg EPS beat(4)14.48%
Min EPS beat(4)-0.6%
Max EPS beat(4)26.47%
EPS beat(8)4
Avg EPS beat(8)-4.65%
EPS beat(12)5
Avg EPS beat(12)-5.54%
EPS beat(16)9
Avg EPS beat(16)1.59%
Revenue beat(2)1
Avg Revenue beat(2)1.56%
Min Revenue beat(2)-1.03%
Max Revenue beat(2)4.14%
Revenue beat(4)3
Avg Revenue beat(4)2.48%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)5.42%
Revenue beat(8)4
Avg Revenue beat(8)-1.81%
Revenue beat(12)5
Avg Revenue beat(12)-3.24%
Revenue beat(16)9
Avg Revenue beat(16)0.93%
PT rev (1m)39.13%
PT rev (3m)23.08%
EPS NQ rev (1m)-11.63%
EPS NQ rev (3m)-9.09%
EPS NY rev (1m)-5.98%
EPS NY rev (3m)-2.69%
Revenue NQ rev (1m)-5.33%
Revenue NQ rev (3m)-8.19%
Revenue NY rev (1m)-0.89%
Revenue NY rev (3m)-0.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B 2.37
P/tB 2.37
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS1.27
BVpS0.38
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.18%
ROE -165.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.04%
FCFM N/A
ROA(3y)-34.86%
ROA(5y)-28.54%
ROE(3y)-98.96%
ROE(5y)-68.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.12%
GM growth 5Y-2.02%
F-Score2
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 2.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 120.53%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 4.56
Altman-Z -0.65
F-Score2
WACC11.99%
ROIC/WACCN/A
Cap/Depr(3y)103.68%
Cap/Depr(5y)91.24%
Cap/Sales(3y)1.6%
Cap/Sales(5y)1.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y37.08%
EPS Next 2Y17.62%
EPS Next 3Y13.24%
EPS Next 5Y18.24%
Revenue 1Y (TTM)-8.12%
Revenue growth 3Y-0.29%
Revenue growth 5Y11.24%
Sales Q2Q%-3%
Revenue Next Year1.58%
Revenue Next 2Y4.61%
Revenue Next 3Y8.36%
Revenue Next 5Y41.4%
EBIT growth 1Y5.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.73%
EBIT Next 3Y31.69%
EBIT Next 5Y28.09%
FCF growth 1Y-224.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-243.82%
OCF growth 3YN/A
OCF growth 5YN/A